Mechanistic Validation of Activin E Targeting De-Risks IBIO-610 and Supports Buy Rating on iBio Shares
I'm PortAI, I can summarize articles.
Analyst Patrick Dolezal from LifeSci Capital has maintained a Buy rating on iBio shares with a $5.00 price target. This rating is supported by promising early-stage results from Arrowhead’s ARO-INHBE program, which showed significant reductions in activin E levels and improvements in body composition. These findings de-risk the mechanism of action for iBio’s IBIO-610 antibody, enhancing confidence in its efficacy and safety for obesity treatment. Dolezal's analysis suggests a favorable risk/reward profile for iBio, justifying the Buy recommendation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments